Despite their close physical and functional relationships, alveolar macrophages (AMs) and pulmonary dendritic cells (pulDCs) have rarely been examined together in the context of infection. Using a nonlethal, resolving model of pneumonia caused by intranasal injection of Streptococcus pneumoniae, we demonstrate that AMs and pulDCs exhibit distinct characteristics during pulmonary inflammation. Recruitment of AMs and pulDCs occurred with different kinetics, and increased numbers of AMs resulted mainly from the appearance of a distinct subset of CD11b
The lungs are a site of primary exposure to both innocuous antigens and potentially harmful pathogens, and local immunoregulatory mechanisms are essential to ensure that immune effector mechanisms remain quiescent or are activated as necessary. The major lung accessory cell populations with immunoregulatory capacity are alveolar macrophages (AMs) [1] and pulmonary dendritic cells (pulDCs) [2, 3] . These populations are linked through both physical proximity [3, 4] and the functional regulation of pulDCs by AMs [5] . However, little information exists concerning the coordinated involvement of AMs and pulDCs during pulmonary immune responses after antigenic challenge. There remains, therefore, a pressing need for the parallel examination of AMs and pulDCs in vivo.
AMs are professional phagocytes residing within the alveoli and are capable of rapidly clearing very large numbers of bacteria from the lungs [6] . AMs regulate the level at which the initiation of a complete inflammatory response occurs. Apoptosis of AMs after exposure to small inoculi ensures resolution of infection without associated inflammation [7] . AMs are also required for a complete protective response against infection with a variety of lung pathogens, including Streptococcus pneumoniae [8] , and may regulate the extent of such responses [9] . During the termination of inflammation, AMs clear cellular debris [8] and restore homeostasis to the lungs. On the basis of the transfer of in vitro differentiated myeloid precursors, Kennedy and Abkovitz have confirmed earlier suggestions that AMs are predominantly derived from circulating blood monocytes [10] . However, neither the kinetics of the replenishment of AMs during and after inflammation nor the molecules regulating these processes have yet been examined. pulDCs are a heterogeneous population composed of "classical" DCs from various pulmonary locations [3] and CD11c
Low plasmacytoid DCs with an immunoregulatory function, which were recently described in a model of asthma [11] . After antigenic challenge, DCs are rapidly recruited to the lungs [12] and migrate to draining lymph nodes [13, 14] . pulDCs are unlikely to play a central role in bacterial clearance, but DCs loaded with S. pneumoniae initiate both T cell-dependent and T cell-independent humoral responses [15] . As has been indicated in studies of influenza virus [16] , it is likely that, in vivo, AMs exert an influence over the nature of pulDC-induced immune responses, even at sites distal from the lungs, such as draining lymph nodes.
In spite of the importance of these two populations of lung accessory cells, no previous study, to our knowledge, has specifically examined both in the same response, and this makes it difficult to draw conclusions about their comparative behavior. In the present study, we phenotypically define AMs and pulDCs in naive mice and in the inflammatory response induced by intranasal (inl) infection with S. pneumoniae [17] . Both the initial inflammation and its subsequent resolution are associated with the influx of a population of AMs with dramatically increased expression of CD11b. Furthermore, we demonstrate that AMs, but not pulDCs, require CD11b for influx into lung tissue after pneumococcal challenge.
MATERIALS AND METHODS
Mice. C57BL/6 mice were bred and housed under barrier conditions at the London School of Hygiene and Topical Medicine and were allowed to eat and drink freely. Animal experimentation was performed with the approval of the London School of Hygiene and Topical Medicine Animal Procedures Ethics Committee and the UK Home Office.
Bacteria. A clinical isolate of S. pneumoniae serotype 6B (Microbiology Department, Royal Free Hospital, London) was used. Bacteria were cultured from frozen glycerol stocks and washed, and numbers of colony-forming units were confirmed as described elsewhere [17] . Mice were placed under light anesthesia and immunized inl with 50 mL of inoculum, which was an infective dose of -cfu. 8 9 1 ϫ 10 1 ϫ 10 Bronchoalveolar lavage (BAL) and tissue preparation. Recovery of BAL fluid was performed as described elsewhere [18] . Mice were killed, and a sterile catheter was inserted into the trachea of each mouse. Lungs were rinsed 6 times with 1.5 mL of sterile PBS containing 0.6 mmol/L EDTA. An additional 2 rinses with fresh PBS/EDTA and a final 2 rinses with PBS were performed, and the fluid from all rinses was pooled. Cells obtained from the pooled fluid were washed in PBS, resuspended in complete medium (RPMI 1640 containing 10% fetal calf serum), and kept on ice until further treatment.
Whole lungs (from which no BAL fluid was harvested) and lung tissue (from which BAL fluid was harvested) were collagenase digested to obtain single-cell suspensions, as described elsewhere [17] . Viable cell counts were determined by trypan blue exclusion.
Flow cytometry and cell sorting. Flow cytometry was performed as described elsewhere [17] , using the following clones and reagents (all from BD Pharmingen unless otherwise stated): HL3 (CD11c); RB6-8C5 (Ly6G/Ly6C; Gr1); F4/80 (macrophage); 2G9 (major histocompatibility complex class II [MHCII]); M1/ 70 (CD11b); murine 7/4 antigen (7/4; Serotec); FA-11 (CD68; Serotec); isotype controls R3-34 (rat IgG1), R35-95 (rat IgG2a), and A95-1 (rat IgG2b); and allophycocyanin-conjugated streptavidin or peridin chlorophyll protein-conjugated streptavidin. All samples were treated with anti-FcRII/III monoclonal antibody (MAb) (clone 2.4G2) before specific staining. Samples were acquired on a FACSCalibur flow cytometer and analyzed with CellQuest Pro software (version 4.0; Becton Dickinson).
For sorting AM and pulDC populations, lung CD11c + cells
were enriched by anti-CD11c beads (Miltenyi Biotech), and magnetic-activated cell sorting was performed in accordance with the manufacturer's recommendations. Cells were sorted using a FACSVantage cell sorter (Becton Dickinson), collected into chilled complete medium, washed, and used immediately for cytospin or in vitro culture procedures. For cytospin slides, ∼ cells in 100 mL of complete 5 1 ϫ 10 medium were spun at 20 g for 10 min onto glass slides by use of a Shandon cytocentrifuge (Thermo). Cytospin slides were stained with Giemsa and analyzed by microscopy and photography using a Zeiss Axioplan microscope, an Optronics CCD camera, and Magnafire SP 2.1B software (Optronics).
For in vitro cultures, sorted cells were plated at a concentration of 1 cells/well in 24-well UltraLow Cluster plates bacteria/mL equivalent), anti-IL-10R (clone 1B1.3a; Pharmingen), and Escherichia coli lipopolysaccharide (LPS; 1 mg/mL; Sigma) were added as required, and cells were incubated in 5% CO 2 at 37ЊC.
CD11b blockade. 5C6 [19] (American Type Culture Collection-LGC Promochem), a nondepleting blocking MAb to CD11b, was affinity purified using protein G. Mice were treated intraperitoneally with 0.25 mg of 5C6 or a nonspecific control MAb 24 h before and at days 2 and 5 after pneumococcal challenge. Treatment of naive mice on an identical schedule did not significantly alter quantitative or qualitative cellular compositions of the lungs, blood, or mediastinal lymph nodes, as determined by flow cytometry (data not shown). High MHCII Int AMs (left panels) and CD11c
High MHCII High pulDCs (right panels) analyzed for forward-/side-scatter characteristics and for expression of murine 7/4 antigen and F4/80. Thin lines show the isotype control, and bold lines show the specific monoclonal antibody. Surface MHCII expression by AMs and pulDCs is shown (thin lines), as well as surface and intracellular MHCII expression (thick lines). All axes represent log fluorescence intensity and representative plots from naive mice. C, Sorted AMs and pulDCs. Cells were prepared as cytospin slides and stained with Giemsa (original magnification, ϫ400). D, Total nos. of AMs (white circles) and pulDCs (black circles). Each graph point represents the . At least 6 mice were analyzed at each time mean ‫ע‬ SD point. * , vs. naive mice (Student's t test). P ! .05
RESULTS

Differential regulation of AMs and pulDCs after pneumococcal challenge.
Although AMs are known to express CD11c [20] , it is often assumed from phenotypic analysis that CD11c
High cells in the lungs are composed of only DCs [21] . Indeed, we have previously defined the CD11c High 
MHCII
Intermediate (Int) cell population as the "pulDC Int " population [17] . Before assessment of the effect that pneumococcal challenge has on AMs and pulDCs, CD11c
High populations were first characterized more extensively, in comparison with splenic CD11c figure 1C) . Collectively, the data allowed us to redefine the "pulDC Int " population as AMs.
We then examined the response of AMs and pulDCs in a High cells analyzed for expression of major histocompatibility complex class II (MHCII; X-axis) and CD11b (Y-axis); gate indicates CD11b
High AMs. Total lung cells from a naive mouse (B) or a mouse challenged 7 days previously with S. pneumoniae (C) were analyzed for expression of Ly6C/Ly6G (Gr1) (X-axis) and CD11b (Y-axis). Gate R1 defines CD11b
High AMs, and gate R2 defines neutrophils. The identification of both populations was confirmed using additional markers in these and parallel 4-color stainings. Plots are representative of 6-18 mice at each time point. All axes represent log fluorescence intensity.
previously established nonlethal, resolving model of pneumonia using inl inoculation of S. pneumoniae serotype 6B [17] , in which a rapid phagocyte response is associated with bacterial clearance in 5-7 days after challenge. As is shown in figure 1D , AMs and pulDCs exhibited distinct kinetics after challenge. Numbers of pulDCs increased rapidly and peaked at day 3 after challenge. After bacterial clearance (day 7-14), numbers of pulDCs decreased and returned to preinfection levels by day 14 after challenge ( figure 1D ). In contrast, numbers of AMs increased steadily during days 1-14 after challenge and were 13-fold higher than those in naive mice at day 14 after challenge. Numbers of AMs eventually returned to the levels in naive mice, and when mice were examined at day 28 after challenge, numbers of AMs in infected mice were indistinguishable from those in naive mice (data not shown). Thus, the kinetics of the recruitment of AMs and pulDCs differed after pneumococcal challenge.
High CD11b expression in AMs. b2 integrins have been associated with the recruitment of inflammatory cells to the lungs [23] [24] [25] . We therefore examined CD11b expression on CD11c
High AMs and pulDCs (figures 2 and 3). In naive mice, AMs were uniformly CD11b
Low cells, whereas CD11b Low and CD11b
High subsets of pulDCs were readily identifiable ( figure  2A, upper left panel) . We then examined how CD11b expression varied during the course of inflammation. Pneumococcal challenge induced the appearance of CD11c High cell population, and CD11b expression levels increased such that, at day 7 after challenge, CD11c High alveolar macrophages (AMs; gated in A, C, and E) and pulDCs (gated in B, D, and F) were obtained from whole lungs of mice challenged 3 days previously with Streptococcus pneumoniae serotype 6B. Gated cells were isolated from each population by flow cytometry to 195% purity. All axes represent log fluorescence intensity. Cytospin slides of CD11b
High AMs (E) and CD11b
High pulDCs (F) were prepared and stained with Giemsa (original magnification, ϫ400).
to a greater extent than did granulocytes within the same sample ( figure 2B and 2C ). These CD11c
High
MHCII
Int CD11b High cells did not express the monocyte/granulocyte-associated antigens Ly6C/Ly6G (figure 2C, R1-gated cells) or 7/4. Smaller, less granular monocytes with expression of both 7/4 and Ly6C/Ly6G antigens were present and clearly distinguishable from these cells (data not shown). Significantly increased numbers of CD11b
High AMs were apparent in the lungs as early as day 1 after challenge, increasing from a mean of 1.14% of the total AMs in naive mice to a mean of 35.1%-62.6% of the total AMs during days 3-14 ( figure 3A) . In contrast, numbers of CD11b Low AMs in infected mice increased slightly only at days 7 and 14 after challenge, compared with those in naive mice.
In contrast to this dramatic appearance of a CD11b High AM population in infected mice, CD11c High 
High CD11b + pulDCs showed decreased CD11b expression in these mice, compared with that in naive mice, as measured by mean fluorescence intensity (MFI), at all time points ( ) except day 7 after P ! .05 challenge ( ) ( for each group; see also figure 2A ). P p .14 n p 6 Furthermore, in naive mice, the CD11b
High and CD11b Low pulDC subsets were present in equivalent numbers (figure 3B). Beginning at day 3 after challenge, numbers of CD11b
High pulDCs increased, and these cells outnumbered CD11b
Low pulDCs at each time point ( figure 3B) . Thus, the increase in the numbers of AMs and pulDCs after pneumococcal challenge was predominantly due to the appearance of CD11b
High cells. To more specifically confirm that these CD11c High 
IntCD11b
High cells were AMs, we sorted this population in lungs of mice at day 3 after challenge. Total CD11c
High cells were gated on the basis of autofluorescence and MHCII expression to define CD11c
High MHCII Int and CD11c High MHCII High cells ( figure 4A and 4B) . These populations had distinct size and granularity characteristics ( figure 4C and 4D ). CD11c cells appeared as a heterologous population with the typical morphological characteristics of monocytic cells or DCs ( figure  4F ). These data confirm that a novel population of AMs expressing very high levels of CD11b appear in the lungs after pneumococcal challenge. This population is homogenous and distinct from the concomitant increase in the numbers of CD11b High pulDCs. To determine whether the appearance of the CD11b High cells described above was compartmentalized within the lungs, we examined BAL fluid and lung tissue (after harvest of the BAL fluid) from individual mice in parallel. In naive mice, AMs were predominantly CD11b
Low cells ( figure 2A ). This finding was also observed when lung tissue and BAL fluid were analyzed separately, with a mean of !2% of the total AMs in either lung tissue or BAL fluid being CD11b
High cells ( figure 5 ). However, pneumococcal challenge increased the proportion of CD11b High AMs to a of in BAL fluid and mean ‫ע‬ SD 66.6% ‫ע‬ 9.9% in lung tissue at day 3 after challenge. 69.8% ‫ע‬ 1.8%
In naive mice, a mean of 1.8% of the cells in BAL fluid were CD11c
High MHCII High cells and were present as a mixture of CD11b
Low and CD11b High cells, which were equivalent in proportions to those in lung tissue or whole lung (figure 2A). At day 3 after challenge, CD11c
High MHCII High cells never exceeded 2% of the total number of cells in the BAL fluid (data not shown). Thus, although the AM population in the BAL fluid alters dramatically after pneumococcal challenge, it appears that pulDCs do not enter the alveoli in high numbers.
Regulation of CD11b. Given the dramatic up-regulation of CD11b on AMs noted above, we sought to determine the underlying mechanism. After inl challenge, viable S. pneumoniae are recoverable from draining lymph nodes, blood, and the spleen for several days [17] . To examine whether infection at these sites had similar effects on CD11b expression by accessory cells, we examined blood, spleens, and lung-draining (mediastinal) lymph nodes from naive mice and from mice at days 3, 7, and 10 after challenge. 
CD11b
High cells is restricted to the lungs (data not shown). The up-regulation of CD11b on AMs could occur either through new protein synthesis or as a result of the transfer of an intracellular pool of existing protein to the cell surface, as occurs with MHCII in DCs [26, 27] . To examine this possibility, AMs and pulDCs from naive mice were examined for intracellular CD11b. No intracellular CD11b was observed in either case, although a significant amount of intracellular MHCII was apparent, as was expected, in pulDCs but not in AMs ( figure 1B and data not shown) . Finally, we addressed whether CD11b expression could be modulated by pathogen-or host-derived stimuli. Two cytokines that are highly associated with AM maturation and function are GM-CSF [28, 29] and IL-10 [30] . Therefore, we incubated purified CD11b
Low AMs and pulDCs overnight with either pathogen-derived stimulation, IL-10, or GM-CSF. Treatment of AMs with S. pneumoniae lysate ( bacteria/well equivalent) or 7 1 ϫ 10 E. coli LPS (1 mg/mL) induced only a slight increase (!30%) in the MFI of CD11b expression. Incubation with IL-10 did not affect CD11b expression by AMs. However, incubation with GM-CSF resulted in a 1120% increase in the MFI of CD11b expression (with medium only: MFI, 411; with LPS: MFI, 520; with GM-CSF: MFI, 904; the results are representative of 2 separate experiments). There was no synergistic effect on CD11b expression when AMs were treated with IL-10 and GM-CSF together. Similarly, inclusion of a blocking MAb to the IL-10 receptor did not affect GM-CSF-mediated up-regulation of CD11b. Expression of CD11b by CD11b
Low pulDCs was unaffected by any of the stimuli (data not shown). These data suggest that high expression of CD11b by AMs could be modulated by the high GM-CSF content of the lung environment rather than by a direct pathogen-mediated effect.
CD11b in pulmonary recruitment of AMs. To determine whether CD11b was functionally relevant for recruitment of AMs and pulDCs, mice were treated with a blocking MAb against CD11b or a control MAb before and after challenge. AM and pulDC populations were examined and quantified in both BAL fluid and lung tissue at day 7 after challenge. In this model, CD11b blockade had no effect on host survival, which was maintained at 100%, and no bacteria were recovered from the lungs of mice treated with either anti-CD11b or a control MAb at this time point.
At day 7 after challenge, mice treated with anti-CD11b showed significantly decreased numbers of both CD11b
High and 
Low AMs within both lung tissue and BAL fluid, compared with those in control mice ( figure 6A and 6B) . The decreases in these numbers in the BAL fluid reflected those observed within the lung tissue, with the numbers of CD11b Low and CD11b
High AMs decreased by 44% and 77%, respectively, in the lung tissue, and the numbers of CD11b
Low and CD11b
High AMs decreased by 47% and 75%, respectively, in the BAL fluid. In contrast, CD11b blockade had no effect on the total numbers of either CD11b Low or CD11b High pulDCs ( figure 6C ). This indicates a distinct requirement for CD11b in the recruitment of AMs, but not pulDCs, during the 7 days after challenge.
DISCUSSION
The outcome of pulmonary antigen exposure is regulated by the balance of AMs and pulDCs, yet, to our knowledge, these populations have not previously been examined in parallel during an immune response. This study demonstrated for the first time that these populations have varied behavior after pneumococcal challenge. Most significantly, we identified several novel aspects of the response of AMs to lung inflammation: S. pneumoniae challenge induces recruitment of CD11b
High AMs, CD11b
High AMs occur in both lung tissue and alveoli, CD11b expression by AMs is regulated by GM-CSF, and CD11b expression is required for entry of AMs or their precursors into the lungs.
We previously identified a pulmonary CD11c
High MHCII Int population as "pulDC Int " cells [17] . In the present study, we demonstrated, through phenotypic, functional, and morphological analyses, that these pulDC Int cells are actually AMs and that CD11c
High MHCII High cells are pulDCs. These data are in agreement with those in a recently published study [22] . AMs and pulDCs exhibit distinct response kinetics to S. pneumoniae challenge in mice. During days 1-3 after challenge, numbers of AMs appear to be relatively stable, whereas pulDCs are recruited to the lungs, just as they are after challenge with heatkilled pathogen [12] . It is likely that the change in numbers of each cell population reflects a balance between the S. pneumoniae-mediated apoptosis of resident AMs [7] and pulDCs [31] , the migration of pulDCs to draining lymph nodes [13, 14] , and the recruitment of new AMs and pulDCs from either the circulating blood [10] or the lung vasculature [32] .
After bacterial clearance, during days 7-14 after challenge, numbers of AMs continued to increase, despite the absence of pathogen. AMs are not only involved in antibacterial activity but also contribute to removing postinflammation debris [33, 34] . Increased numbers of AMs may contribute to wound healing through increased production of anti-inflammatory cytokines, including transforming growth factor-b [33] . In addition, resolution-associated AM recruitment may protect against opportunistic secondary infections. In contrast, by day 14 after challenge, numbers of pulDCs approached those in naive mice, suggesting that pathogen load and inflammatory stimuli are the primary criteria driving turnover of pulDCs.
Pneumococcal challenge results in the rapid appearance of a novel, lung-restricted, CD11c High 
MHCII
Int CD11b High AM population. Expression of CD11b by AMs is in itself unusual, because these cells are characterized as CD11b Ϫ [35, 36] . CD11b expression is more commonly associated with influxing neutrophils and monocytes [35] [36] [37] [38] . However, CD11b High AMs did not express the granulocyte/monocyte-associated 7/4 and Ly6C/ Ly6G antigens, which are highly expressed by monocytes [36] . Furthermore, the concurrent expression of CD11c by these cells, their size and granularity, and, most obviously, their morphological characteristics confirm that they are a novel population of AMs.
Increased numbers of pulDCs at early time points also result from increased numbers of CD11b
High cells. In the spleen, bacterial infection may predominantly recruit one DC subset rather than another [39] . Our results suggest that this also occurs in the lungs after S. pneumoniae challenge, with CD11b
High pulDCs dominating. By documenting the response well into the resolution phase, we demonstrated that this imbalance in the normal ratio of the DC subsets is temporary. Recruitment of specific DC subsets may have significant consequences for the nature of subsequent adaptive immune responses [40] . What those consequences may be with regard to antipneumococcal responses initiated by CD11b
High pulDCs, rather than CD11b High cells are not found in blood, and our observation that CD11b blockade also decreased the numbers of CD11c
High CD11b
Low AMs does not support this model. Instead, monocytic precursors may acquire the AM phenotype (i.e., the acquisition of CD11c) during maturation in transit from the bloodstream to the lung tissue, similar to what happens when DCs differentiate as they cross endothelium in vitro [41] . These AMs would be CD11b
Low cells by default but are driven to become CD11b
High cells by inflammation-associated increased levels of GM-CSF. GM-CSF is critical for the functional maturation of AMs in vivo [28, 29] and is significantly up-regulated during pulmonary inflammation [42] and specifically during pneumococcal stimulation [43] . A "naive" AM population may be restored through either death of CD11b High AMs or down-regulation of CD11b expression as GM-CSF levels normalize. Although we support this latter model, a model in which CD11b
Low and CD11b High AMs are generated from distinct monocytic precursor populations cannot be discounted. Independent of the above, CD11b expression by AMs is functionally crucial for recruitment of AMs during inflammation, and this function is not shared by CD11b
High pulDCs. In previous studies, the rapid influx of monocytes and neutrophils into the lungs and alveoli after exogenous stimulation has been shown to exhibit variable dependence on CD11b expression [23, 35] . Because neutrophils may be dispensable for pneumococcal clearance [17] , the data in the present study may further explain the increased susceptibility of Mac-1-deficient (CD11b/CD18) [44] and CD11b-deficient [45] mice to S. pneumoniae infection. However, the nonlethal, resolving model of pneumonia is perhaps inappropriate for addressing any specific antibacterial role played by the CD11b expression of AMs. Notably, CD11b blockade reduced the numbers of not only CD11b
High AMs but also CD11b Low AMs in the lungs. Although the stage of AM migration into the lung during which CD11b expression is required is unknown, that CD11b
High AMs exhibit comparable distribution in lung tissue and BAL fluid suggests a distinct requirement for CD11b before AMs enter the alveoli. Finally, whether adhesion molecule activity is the only function of CD11b when expressed on AMs is unknown. AMs may up-regulate CD11b to facilitate C3b-mediated opsonization of pneumococci [46] . During resolution, this opsonic activity may function to aid the uptake by AMs of apoptotic and dead cells, such as neutrophils. However, CD11b blockade did not affect bacterial clearance in this model and may not be central to this process.
Thus, AM and pulDC populations exhibit differential kinetics, differential access to alveoli, and differential requirements for CD11b during recruitment. These data provide a basis for further critical examination of the distinct roles that AMs and pulDCs play in initiating and regulating innate and adaptive pulmonary immune responses.
